Skip to Main Content

Zealand Pharma on Thursday reported early positive results of an investigational obesity drug that activates a hormone that’s not targeted by popular treatments Wegovy and Zepbound.

In one part of a Phase 1b study, petrelintide, which targets the amylin hormone, led to 8.6% weight loss at 16 weeks, more than the 1.7% weight loss among patients taking placebo, the Danish company said.


Though these are early findings, they show that Zealand’s injectable treatment has potential to deliver substantial weight loss, possibly helping it to compete with blockbuster treatments from Novo Nordisk and Eli Lilly. Zealand is also hoping petrelintide will be more tolerable than the obesity drugs on the market, which can cause nausea and vomiting.

STAT+ Exclusive Story


This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in



Totals $468 per year

$39/month Get Started

Totals $468 per year



for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month



Save 15%

$399/year Get Started

Save 15%

11+ Users


Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users


Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.


STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.